Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Autodesk Inc (ADSK) vs Novavax Inc (NVAX) Price & Performance

Autodesk Inc
Novavax Inc

Price performance

Price movement over the last 24 hours

Key statistics

Autodesk Inc vs Novavax Inc — how do they compare? Autodesk Inc trades at $206.41 (market cap $44.84B), while Novavax Inc trades at $9.34 (market cap $1.56B). The key difference: Autodesk Inc is far larger — about 28.7× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Autodesk Inc nearer its low. Which is the better fit depends on your goals.

ADSKNVAX
Market Cap
$44.84B$1.56B
Sector
TechnologyHealth
52-Week High
$326.79$11.19
52-Week Low
$187.72$6.22
Enterprise Value
$44.64B$1.06B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Autodesk Inc

Autodesk (ADSK) trades at $212.38, up 2.36% today, with strong fundamentals including 91.14% gross margins and consistent earnings beats. The stock shows bullish technical signals near resistance at $213, supported by positive analyst sentiment and strategic AI investments. Recent news highlights the MaintainX acquisition and AWS partnership, expanding the company's market reach.

Outlook remains positive with a consensus price target of $308.86, though risks include high valuation multiples and competitive pressures. Earnings growth and AI integration present opportunities, but investors should monitor execution risks and market volatility.

Novavax Inc

Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.

Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.

Returns comparison

Trailing returns across standard periods

About Autodesk Inc

Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction.

Read more on ADSK

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX